| |
著者: Aurélia Henn, Clara Flateau, Sébastien Gallien
雑誌名: Curr Infect Dis Rep. 2017 Sep 7;19(10):37. doi: 10.1007/s11908-017-0588-3. Epub 2017 Sep 7.
Abstract/Text
PURPOSE OF REVIEW: The purpose of this review was to provide current data on clinical presentation, diagnosis, and treatment of primary HIV infection (PHI).
RECENT FINDINGS: In 65 to 95% of cases, PHI causes acute retroviral syndrome presenting with unspecific flu-like symptoms. Symptomatic PHI was associated with a faster clinical and immunological progression of HIV infection. Point-of-care tests remain less sensitive than fourth-generation immunoassays (IA) in PHI, especially after tenofovir-based prophylaxis use. Early antiretroviral treatment (ART) started during PHI prevents HIV transmission and decreases viral and immunological reservoir constitution. Recommended ART regimens in PHI are combinations of tenofovir and emtricitabine with either darunavir/ritonavir, or dolutegravir. Starting ART the earliest is highly recommended for clinical, virological, immunological, and public health benefits. Reducing HIV reservoir constitution in PHI may optimize potential opportunities for future functional cure.
PMID 28884279 Curr Infect Dis Rep. 2017 Sep 7;19(10):37. doi: 10.1007/s11908-017-0588-3. Epub 2017 Sep 7.
|
